How to buy Aptose Biosciences (APTO) stock

Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 39 staff and has a market cap (total outstanding shares value) of 0.00.

Aptose Biosciences stock price (NASDAQ: APTO)

Use our graph to track the performance of APTO stocks over time.

Aptose Biosciences shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$5.30
52-week range	$2.75 - $7.27
50-day moving average	$3.65
200-day moving average	$4.47
Wall St. target price	$4.72
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.59

Buy Aptose Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aptose Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aptose Biosciences Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptose Biosciences price performance over time

Historical closes compared with the close of $5.3 from 2021-05-28

1 week (2021-07-13)	N/A
1 month (2021-06-24)	55.43%
3 months (2021-04-20)	N/A
6 months (2021-01-20)	N/A

1 year (2020-07-20)	N/A
2 years (2019-07-20)	N/A
3 years (2018-07-20)	N/A
5 years (2016-07-20)	N/A

Aptose Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-36.21%
Return on equity TTM	-60.96%
Profit margin	0%
Book value	$1.23
Market capitalisation	$252.3 million

TTM: trailing 12 months

Shorting Aptose Biosciences shares

There are currently 2.9 million Aptose Biosciences shares held short by investors – that's known as Aptose Biosciences's "short interest". This figure is 4.1% down from 3.0 million last month.

There are a few different ways that this level of interest in shorting Aptose Biosciences shares can be evaluated.

Aptose Biosciences's "short interest ratio" (SIR)

Aptose Biosciences's "short interest ratio" (SIR) is the quantity of Aptose Biosciences shares currently shorted divided by the average quantity of Aptose Biosciences shares traded daily (recently around 1.8 million). Aptose Biosciences's SIR currently stands at 1.59. In other words for every 100,000 Aptose Biosciences shares traded daily on the market, roughly 1590 shares are currently held short.

However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptose Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aptose Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0424% of the tradable shares (for every 100,000 tradable Aptose Biosciences shares, roughly 42 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptose Biosciences.

Find out more about how you can short Aptose Biosciences stock.

Aptose Biosciences share dividends

We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.

Have Aptose Biosciences's shares ever split?

Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.

Aptose Biosciences share price volatility

Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $2.75 up to $7.27. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.2301. This would suggest that Aptose Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Aptose Biosciences overview

Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc.

Frequently asked questions

What percentage of Aptose Biosciences is owned by insiders or institutions?
Currently 5.067% of Aptose Biosciences shares are held by insiders and 60.681% by institutions. How many people work for Aptose Biosciences?
Latest data suggests 39 work at Aptose Biosciences. When does the fiscal year end for Aptose Biosciences?
Aptose Biosciences's fiscal year ends in December. Where is Aptose Biosciences based?
Aptose Biosciences's address is: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 What is Aptose Biosciences's ISIN number?
Aptose Biosciences's international securities identification number is: CA03835T2002 What is Aptose Biosciences's CUSIP number?
Aptose Biosciences's Committee on Uniform Securities Identification Procedures number is: 03835T101